查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951262

新一代體外診斷市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、產品、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Next-Generation In-vitro Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球新一代體外診斷市場預計將從 2025 年的 927.9 億美元成長到 2031 年的 1,549.3 億美元，複合年成長率為 8.92%。

新一代體外診斷（IVD）利用先進的分析評估技術，結合分子、基因組和高通量調查方法，能夠以極高的速度和準確性從生物檢體中識別疾病。該行業的主要驅動力是日益成長的個人化醫療和疾病早期檢測需求，從而實現精準的治療策略。此外，全球感染疾病和慢性病發病率的不斷上升也是一個關鍵促進因素，迫使醫療基礎設施將這些精準診斷設備納入標準臨床工作流程，以改善患者的治療效果。

市場概覽
預測期 2027-2031
市場規模：2025年 927.9億美元
市場規模：2031年 1549.3億美元
複合年成長率：2026-2031年 8.92%
成長最快的細分市場 分子診斷
最大的市場 北美洲

然而，由於監管環境嚴格且不斷變化，對製造商施加了沉重的合規義務，市場成長面臨許多障礙。獲得核准的高昂成本和複雜流程可能會延緩新技術的發布，並限制創新者進入市場。這種監管負擔迫使企業投入大量資源來滿足新的標準。根據 MedTech Europe 的一份報告，2024 年的一項調查顯示，79% 的體外診斷製造商已對其至少部分產品線進行了修改，以符合體外診斷醫療設備法規 (IVDMR) 的嚴格要求。

市場促進因素

感染疾病和慢性病的日益增多是推動全球下一代體外診斷市場發展的主要動力。醫療系統越來越依賴先進的診斷技術來應對癌症等疾病的不斷蔓延，這就需要靈敏度更高、出結果更快的設備。疾病發生率的上升促使人們必須採用基因組和分子檢測技術，以便更早進行治療，提高患者的存活率。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》，預計2024年美國新增癌症病例約為2,001,140例，這凸顯了早期識別惡性腫瘤所需的精準診斷工具的緊迫性。

此外，將機器學習和人工智慧融入診斷流程將提高營運效率和分析準確性，從而加速市場擴張。這些技術有助於實現複雜數據分析的自動化，尤其是在數位病理學和基因組學領域，從而減少人為錯誤並減輕實驗室技術人員的負擔。截至2024年8月，美國食品藥物管理局（FDA）已核准950種採用人工智慧和機器學習醫療設備，顯示計算工具在診斷領域的應用正在迅速普及。這種技術整合不僅提高了診斷準確性，還透過提升生產力增強了產業的財務狀況。正如生物梅里埃在2024年4月發布的《2024年第一季業務回顧》中所顯示，臨床診斷解決方案的穩定普及帶來了9.8%的有機銷售額成長。

市場挑戰

嚴格且不斷變化的法規結構是限制全球下一代體外診斷市場發展的主要阻礙因素。製造商必須經歷複雜的核准程序，這些程序要求提供大量的臨床概念驗證和詳盡的文檔，導致營運成本顯著增加，研發週期延長。這種合規負擔迫使企業將大量資源從產品創新和研發轉移到滿足政府的要求。因此，先進診斷技術的市場推廣往往被延遲，減緩了新解決方案的上市速度，並造成了不確定性抑制了對潛在顛覆性技術的投資。

這些監管負擔直接影響策略規劃和市場部署，有效阻礙了下一代診斷設備在全球的普及。 2024年，《歐洲醫療技術》雜誌報告稱，與先前的法規結構相比，主要體外診斷試劑製造商選擇歐盟作為其首發市場的比率下降了40%。這一急劇下降表明，日益增多的監管障礙阻礙了企業優先發展關鍵市場，從而影響了整個行業的成長前景，並限制了人們獲得必要的診斷檢測。

市場趨勢

全球新一代體外診斷市場正經歷重大轉型，從傳統醫院實驗室以外的快速診斷需求轉向照護現場檢測（POC​​）和分散式分子檢測。這一趨勢的特點是小型自動化分子檢測設備在藥房、急診中心和診所的廣泛應用，從而為感染疾病提供即時治療方案。這種結構性變化減少了與中心檢查室處理相關的物流延誤，並提高了患者在社區環境中獲得複雜檢測的便利性。丹納赫公司於2024年10月發布的2024年第三季財報顯示，其Cefeed部門僅呼吸道檢測一項就創造了4.25億美元的收入，這充分證明了市場對這些便捷檢測方式的持續需求，也體現了患者就近分子檢測的顯著普及。

同時，用於評估微量殘存疾病(MRD) 和非侵入性癌症後續觀察的液態生物檢體技術正呈現爆炸性成長。醫療專業人員擴大使用循環腫瘤 DNA (ctDNA) 分析來監測治療反應並早期發現復發，從而實現比放射影像學更早識別復發，進而實現更精準的癌症治療。這種從血液樣本進行基因組分析的轉變，減少了對侵入性組織切片檢查的需求，同時提供了腫瘤進展的即時數據。 2024 年 11 月，Natera 在 2024 年第三季財報中宣布，該季度進行了約 137,100 例腫瘤檢測。與去年同期相比，這一數字顯著成長了 54.4%，主要得益於該公司個人化液態生物檢體解決方案的臨床應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球下一代體外診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（核心檢查室診斷、即時檢驗、分子診斷、其他）
    • 依產品分類（耗材、設備、軟體）
    • 依應用領域（腫瘤/癌症、感染疾病、糖尿病、心臟病、其他）
    • 依最終使用者（醫院/診所、診斷檢查室、學術研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美下一代體外診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲下一代體外診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區下一代體外診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲下一代體外診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲下一代體外診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球下一代體外診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson, and Company
  • Qiagen GmbH
  • Illumina Inc.
  • Beckman Coulter, Inc.
  • Invivoscribe, Inc.
  • Sysmex Corporation
  • bioMerieux SA
  • VWR International, LLC.
  • Danaher Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23857

The Global Next-Generation In-vitro Diagnostics Market is projected to expand from a valuation of USD 92.79 Billion in 2025 to USD 154.93 Billion by 2031, reflecting a CAGR of 8.92%. Next-Generation In-vitro Diagnostics (IVD) involve sophisticated analytical assessments on biological specimens, leveraging molecular, genomic, and high-throughput methodologies to identify diseases with superior speed and accuracy. The industry is principally driven by the escalating need for personalized medicine and early disease identification, which facilitates specific therapeutic strategies. Additionally, the growing worldwide incidence of infectious diseases and chronic conditions acts as a vital accelerator, forcing healthcare infrastructures to incorporate these precise diagnostic instruments into standard clinical workflows to enhance patient results.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 92.79 Billion
Market Size 2031USD 154.93 Billion
CAGR 2026-20318.92%
Fastest Growing SegmentMolecular Diagnostics
Largest MarketNorth America

Nevertheless, market growth faces substantial hurdles due to a rigid and shifting regulatory landscape that imposes heavy compliance obligations on manufacturers. The substantial expense and intricacy involved in securing approvals can postpone the release of new technologies and restrict market entry for innovators. This regulatory strain compels firms to allocate considerable assets toward meeting emerging standards. As reported by MedTech Europe, a 2024 survey revealed that 79% of IVD producers had shifted at least a portion of their product lines to align with the stringent In Vitro Diagnostic Medical Devices Regulation.

Market Driver

The escalating prevalence of infectious and chronic diseases serves as a major impetus for the Global Next-Generation In-vitro Diagnostics Market. Healthcare frameworks increasingly depend on sophisticated diagnostic techniques to handle the rising load of conditions like cancer, requiring instruments that provide superior sensitivity and rapid results. This increase in disease occurrence mandates the implementation of genomic and molecular testing to enable early treatment and enhance patient survival. Data from the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, estimated roughly 2,001,140 new cancer diagnoses in the United States for the year, highlighting the urgent requirement for accurate diagnostic tools to identify malignancies in their initial phases.

Furthermore, incorporating machine learning and artificial intelligence into diagnostic processes hastens market expansion by improving operational efficiency and analytical accuracy. These technologies facilitate the automation of intricate data analysis, especially within digital pathology and genomics, which diminishes human error and reduces the burden on laboratory staff. By August 2024, the U.S. Food and Drug Administration had authorized 950 medical devices enabled by artificial intelligence and machine learning, indicating the swift adoption of computational tools in diagnostics. This technological convergence not only sharpens diagnostic precision but also bolsters the sector's financial health through heightened productivity, as evidenced by bioMerieux's April 2024 'First-Quarter 2024 Business Review', which reported a 9.8% organic sales increase driven by the steady uptake of clinical diagnostic solutions.

Market Challenge

A rigid and changing regulatory framework acts as a notable constraint on the Global Next-Generation In-vitro Diagnostics Market. Manufacturers must move through intricate approval procedures that demand extensive clinical proof and thorough documentation, resulting in considerably higher operational expenses and longer development cycles. This weight of compliance obliges companies to divert essential resources away from product innovation and development to satisfy administrative prerequisites. As a result, the market introduction of sophisticated diagnostic technologies is frequently postponed, slowing the rate at which novel solutions become available and creating uncertainty that discourages investment in potentially revolutionary innovations.

Such regulatory strain directly influences strategic planning and market reach, effectively hindering the worldwide spread of next-generation diagnostic instruments. In 2024, MedTech Europe reported that the percentage of major IVD manufacturers selecting the European Union as their initial launch region fell by 40% compared to earlier regulatory frameworks. This precipitous drop illustrates how intensified regulatory hurdles dissuade firms from prioritizing key markets, thereby impeding the industry's overall growth prospects and restricting access to essential diagnostic tests.

Market Trends

The Global Next-Generation In-vitro Diagnostics Market is experiencing a major transition toward point-of-care and decentralized molecular testing, fueled by the need for quick diagnostic results outside of conventional hospital labs. This movement is defined by the extensive implementation of small, automated molecular units in pharmacies, urgent care facilities, and clinics, enabling immediate therapeutic choices for infectious diseases. This structural shift lessens logistical lags linked to central lab processing and enhances patient access to complex testing in local environments. Highlighting the ongoing need for these accessible options, Danaher Corporation's 'Third Quarter 2024 Earnings Results' from October 2024 noted that its Cepheid division produced $425 million in revenue from respiratory testing alone, indicating a substantial volume of near-patient molecular tests.

Simultaneously, there is a surge in the utilization of liquid biopsy technologies for minimal residual disease (MRD) assessment and non-invasive cancer tracking. Medical professionals are increasingly employing circulating tumor DNA (ctDNA) analysis to monitor treatment efficacy and identify recurrence much sooner than radiological imaging, thus allowing for more exact oncological care. This shift toward genomic profiling via blood samples reduces the necessity for invasive tissue biopsies while offering real-time data on tumor progression. In November 2024, Natera, Inc. reported in its 'Third Quarter 2024 Financial Results' that it conducted roughly 137,100 oncology tests during the quarter, marking a significant 54.4% rise from the previous year, largely fueled by the clinical adoption of its personalized liquid biopsy offerings.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson, and Company
  • Qiagen GmbH
  • Illumina Inc.
  • Beckman Coulter, Inc.
  • Invivoscribe, Inc.
  • Sysmex Corporation
  • bioMerieux SA
  • VWR International, LLC.
  • Danaher Corporation

Report Scope

In this report, the Global Next-Generation In-vitro Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation In-vitro Diagnostics Market, By Type

  • Core Laboratory Diagnostics
  • PoC Testing
  • Molecular Diagnostics
  • Others

Next-Generation In-vitro Diagnostics Market, By Product

  • Consumables
  • Instruments
  • Software

Next-Generation In-vitro Diagnostics Market, By Application

  • Oncology/Cancer
  • Infectious Diseases
  • Diabetes
  • Cardiology
  • Others

Next-Generation In-vitro Diagnostics Market, By End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Others

Next-Generation In-vitro Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation In-vitro Diagnostics Market.

Available Customizations:

Global Next-Generation In-vitro Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation In-vitro Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Core Laboratory Diagnostics, PoC Testing, Molecular Diagnostics, Others)
    • 5.2.2. By Product (Consumables, Instruments, Software)
    • 5.2.3. By Application (Oncology/Cancer, Infectious Diseases, Diabetes, Cardiology, Others)
    • 5.2.4. By End User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutions, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Next-Generation In-vitro Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next-Generation In-vitro Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Next-Generation In-vitro Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Next-Generation In-vitro Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Next-Generation In-vitro Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next-Generation In-vitro Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Next-Generation In-vitro Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Next-Generation In-vitro Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Next-Generation In-vitro Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Next-Generation In-vitro Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Next-Generation In-vitro Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Next-Generation In-vitro Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Next-Generation In-vitro Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Next-Generation In-vitro Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Next-Generation In-vitro Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Next-Generation In-vitro Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Next-Generation In-vitro Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Next-Generation In-vitro Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Next-Generation In-vitro Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Next-Generation In-vitro Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Next-Generation In-vitro Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Next-Generation In-vitro Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Next-Generation In-vitro Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Next-Generation In-vitro Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Next-Generation In-vitro Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton, Dickinson, and Company
  • 15.3. Qiagen GmbH
  • 15.4. Illumina Inc.
  • 15.5. Beckman Coulter, Inc.
  • 15.6. Invivoscribe, Inc.
  • 15.7. Sysmex Corporation
  • 15.8. bioMerieux SA
  • 15.9. VWR International, LLC.
  • 15.10. Danaher Corporation

16. Strategic Recommendations

17. About Us & Disclaimer